{"id":233,"date":"2024-02-09T20:32:28","date_gmt":"2024-02-09T20:32:28","guid":{"rendered":"https:\/\/www.libertymanagement.us\/fda-news\/?p=233"},"modified":"2024-02-09T20:32:28","modified_gmt":"2024-02-09T20:32:28","slug":"drug-reporting-final-guidance","status":"publish","type":"post","link":"https:\/\/www.libertymanagement.us\/fda-news\/2024\/02\/09\/drug-reporting-final-guidance\/","title":{"rendered":"DRUG REPORTING FINAL GUIDANCE"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">FDA has\nissued a new guidance on <a href=\"https:\/\/www.fdahelp.us\/fda-drug-reporting.html\">drug reporting<\/a>\nunder which registrants of drug establishments are required to submit reports\non the amount of each listed drug manufactured, prepared, propagated,\ncompounded, or processed for commercial distribution, as required by section\n510(j)(3) of FD&amp;C act.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As per the\nguidance, the registrants are required to submit a list of all drugs they\nmanufacture, prepare, propagate, compound, or process for commercial\ndistribution annually. This list must include the name and <a href=\"https:\/\/www.fdahelp.us\/fda-labeler-code.html\">National Drug Code (NDC<\/a>) of each drug, as well as other information such as the\ndosage form, strength, route of administration, and package size.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In the\nguidance FDA refers \u201cRegistrant\u201d as any person that owns or operates an\nestablishment that manufactures, repacks, relabels, or salvages a drug, and is\nnot otherwise exempt from establishment registration requirements under section\n510 of the FD&amp;C Act or 21 CFR part 207. See \u00a7 207.1.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FDA requires\nall registrant of <a href=\"https:\/\/www.fdahelp.us\/fda-drug-registration.html\">drug establishment<\/a> which includes prescription drugs,\nover the counter (OTC) drugs, and biologic products, re-packers and\nre-labelers, <a href=\"https:\/\/www.fdahelp.us\/api-listing.html\">active pharmaceutical ingredient (API)<\/a>, and other types of listed drugs,\nmedical gases, <a href=\"https:\/\/www.fdahelp.us\/homeopathic-drug-listing.html\">homeopathic products<\/a>, animal drug products, and\ndistributors to submit drug reporting to the agency.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For private\nlabel distributors, the data should be submitted separately by the NDC\nassociated with the registrant\u2019s labeler code and the NDC associated with the\nprivate label distributor\u2019s labeler code.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Reports on\nthe amount of each registrant\u2019s listed drugs must be submitted yearly. Such\nreports should include information regarding the amount of drug released for\nthe respective calendar year (January 1 \u2013 December 31) and should be submitted\nno later than March 31st of the following fiscal year.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"http:\/\/www.fdahelp.us\">Liberty Management Grou<\/a>p, as a leading FDA consulting firm, can help you in submitting the drug reports to FDA on time.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sudha S<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Regulatory Consultant<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Email : office@libertymanagement.us<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">www.fdahelp.us<a href=\"http:\/\/www.fdahelp.us\">http:\/\/www.fdahelp.us<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA has issued a new guidance on drug reporting under which registrants of drug establishments are required to submit reports on the amount of each listed drug manufactured, prepared, propagated, compounded, or processed for commercial distribution, as required by section 510(j)(3) of FD&amp;C act. As per the guidance, the registrants are required to submit a &hellip; <a href=\"https:\/\/www.libertymanagement.us\/fda-news\/2024\/02\/09\/drug-reporting-final-guidance\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DRUG REPORTING FINAL GUIDANCE&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[33],"class_list":["post-233","post","type-post","status-publish","format-standard","hentry","category-fda-registration-drug","tag-fda-drug-reporting"],"_links":{"self":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/comments?post=233"}],"version-history":[{"count":1,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/233\/revisions"}],"predecessor-version":[{"id":234,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/posts\/233\/revisions\/234"}],"wp:attachment":[{"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/media?parent=233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/categories?post=233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-news\/wp-json\/wp\/v2\/tags?post=233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}